Organizing Committee
Carlos Porras, Malaga
Hans - Joachim Schäfers, Homburg (Germany)
José Mª Hernández, Málaga
Malaga Valve 2017
Faculty
Hans - Joachim Schäfers, Homburg (Germany)
Carlos Porras, Málaga (Spain)
Jose María Hernández, Málaga (Spain)
Eduardo de Teresa, Málaga (Spain)
Lorenzo Montserrat, La Coruña (Spain)
Borja Fernández, Málaga (Spain)
Pilar Tornos, Barcelona (Spain)
Arturo Evangelista, Barcelona (Spain)
Fernando Cabrera, Málaga (Spain)
Irem Karliova, Homburg (Germany)
Hans R Figulla, Jena (Germany)
Raphael Rosenhek, Vienna (Austria)
Gilles Dreyfus, Montecarlo (Monaco)
Marta Sitges, Barcelona (Spain)
Stephan Baldus, Cologne (Germany)
Gemma Sánchez Espín, Málaga (Spain)
Jose Luis Pomar, Barcelona (Spain)
Eduardo Moreno, Granada (Spain)
Juan J Gómez Doblas, Málaga (Spain)
Miguel Such, Málaga (Spain)
José M García Pinilla, Málaga (Spain)
Robert Klautz, Leids (Holland)
Maria Jose Mataró, Málaga (Spain)
Fernando Carrasco, Málaga (Spain)
Ricardo Fajardo, Almería (Spain)
Eulogio García, Madrid (Spain)
José Luis Zunzunegui, Madrid (Spain)
Sergio Cánovas,, Murcia (Spain)
Thierry Bourguignon, Tours (France)
Antonio Muñoz, Málaga (Spain)
César Moris, , Oviedo (Spain)
Manuel Pan, Córdoba (Spain)
Johanna J.M. Takkenberg, Rotterdam (Holland)
Emiliano Rodríguez-Caulo, Málaga (Spain)
A journey into contemporary heart valve therapies
confirm your attendance to the following email:
Please,
[email protected]
Edwards, Edwards Lifesciences and the stylized E logo are trademarks or services marks of
Edwards Lifesciences Corporation.
29-31 March 2017
Hotel NH Malaga
Calle San Jacinto, 2
Malaga
On behalf of the Organizing Committee it is a great pleasure for us to invite you to
attend the Malaga Valve 2017 that will be held next March 29-31 in Malaga, Spain.
With this meeting we aim to join prominent leaders in Heart Valve Diseases
in order to share knowledge, reinforce professional and personal links and
to improve the appliance to clinical practice of the latest advances in the
Heart Valve Diseases area.
Malaga Valve meeting intends to attract clinical cardiologists, image
cardiologists, cardiac surgeons and all the professionals involved in the
care of valve disease patients.
© 2016 Edwards Lifesciences Corporation. All rights reserved. ENP188/05-16/HVT
Looking forward to seeing you soon.
Edwards LifesciencesŦ4QWVGFGNş'VTC\0[QP5YKV\GTNCPFŦGFYCTFUEQO
Carlos Porras - On behalf of the Organizing Committee
Malaga Valve 2017
A journey into contemporary heart valve therapies
HOTEL NH Málaga
Wednesday, March 29th – Friday, March 31st, 2017
Chairmen: Prof. Hans-Joachim Schäfers/Dr. Carlos Porras/Dr. Jose María Hernández
Wednesday March 29 th , 2017
13.00-14.00
Lunch
Introductory session
Moderators : H.-J. Schäfers / E. de Teresa
14.00-14.10
Welcome
H.J Schäfers/E. de Teresa
14.15-14.30
Late breaking news in heart valve disease
E. de Teresa
14.30-14.45
Genetics and Heart valve disease
L. Monserrat
14.45-15.00
Bicuspid aortic valves and more. The biologic basis
15.00-15.30
Discussion
B. Fernández
Aortic regurgitation and aortic root pathology
Moderators: H.-J. Schäfers / P.Tornos
15.30-15.45
Should we change the current guidelines?
15.45-16.00
Medical treatment in Marfan syndrome, an update
16.00-16.15
Marfan syndrome requires specialized units
16.15-16.30
Imaging for ascending aorta and aortic valve
16.30-17.10
Discussion
17.10-17.40
Break
P.Tornos
A.Evangelista
F. Cabrera
A.Evangelista
17.40-17.55
Aortic Valve Repair: Is it worthwhile the effort?
H.-J. Schäfers
17.55-18.10
A good replacement is better than a bad repair
I. Karliova
18.10-18.25
TAVI should replace surgery in aortic regurgitation
H.-R. Figulla
18.25-18.35
Clinical case and voting to start the discussion
C.Porras
18.35-19.20
Discussion
21.00
Welcome drink and group dinner
Thursday March 30 th , 2017
Mitral valve: Structural
Moderators : R. Rosenhek, G.Dreyfus
08.35-08.50
Timing of surgery - early or late?
08.50-09.05
Imaging as the basis for intervention or surgery
09.05-09.20
Surgery in structural MR: The gold standard
G. Dreyfus
09.20-09.35
Percutaneous approach: where are we now?
S. Baldus
09.35-09.45
Clinical case and voting to start the discussion
09.45-10.45
Discussion
10.45-11.00
Break
Tricuspid valve
R. Rosenhek
M.Sitges
G. Sanchez-Espín
Moderators : J.-L. Pomar, E. Moreno
11.05-11.20
Is tricuspid regurgitation a benign disease? When is it the
right time to operate on the patient?
11.20-11.35
Imaging and mechanisms and predictors of repair failure
11.35-11.50
Is there a role for elective tricuspid valve replacement?
11.50-12.05
Percutaneous approach: where are we now?
12.05-12.15
Clinical case and voting to start the discussion
12.15-13.15
Discussion
13.15-14.15
Lunch
J. Gómez Doblas
M. Sitges
G. Dreyfus
S. Baldus
M. Such
Mitral valve: Functional
Moderators : J.-L. Pomar, M. Sitges
14.15-14.30
Pathophysiology and Imaging in FMR
14.30-14.45
Efficacy of Medical treatment and resynchronization
therapy in FMR
14.45-15.00
Mitraclip and other percutaneous devices are a stable
solution for FMR
15.00-15.15
FMR needs more than annuloplasty
15.15-15.30
Surgical annuloplasty is the preferred approach to FMR
15.30-15.40
Clinical case and voting to start the discussion
15.40-16.40
Discussion
16.40-17.00
Break
Miscellanea
M. Sitges
JM. García Pinilla
S. Baldus
H.-J. Schäfers
R. Klautz
Mª Jose Mataró /
Fernando Carrasco
Moderators : R. Fajardo / J.M. Hernández
17.00-17.15
Percutaneous treatment of paravalvular leaks: Approaches, imaging and results
E. García
17.15-17.30
Interventions on the Pulmonary valve
17.30-18.00
Discussion
20.30
Dinner. Restaurante el Pimpi.
JL. Zunzunegui
Friday March 31 st , 2017
Aortic stenosis
Moderators : H.-R. Figulla / S. Cánovas
09.05-09.20
Indications for treatment in AS - need for change?
09.20-09.35
Expanded indications for tissue prostheses: the end of
mechanical valves?
09.35-09.50
Aortic baloon valvuloplasty: still a reasonable tool?
09.50-10.05
TAVI in low risk and in younger patients
10.05-10.20
MIS surgery and rapid deployment valves: Impact on patient
selection for TAVI and surgery
10.20-10.40
Break
10.40-10.55
Complications of TAVI procedures: Prognostic implications
10.55-11.10
What does the patient expect from the treatment of AS?
11.10-11.20
Clinical case and voting to start the discussion
11.20-12.50
Discussion
R. Rosenhek
T. Bourguignon
A. Muñoz
C. Morís
S. Cánovas
M. Pan
J. Takkenberg
E. Rodríguez-Caulo
12.50- 13.00 Closing remarks
Clinical Cardiologist: Juan José Gómez Doblas
Interventional Cardiologist: José María Hernández
Surgeon: Carlos Porras
13.00-14.00 Lunch
Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation
or its affiliates. All other trademarks are the property of their respective owners.
© 2016 Edwards Lifesciences Corporation. All Rights reserved.
Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com
Supported by: